Seres Therapeutics (NASDAQ:MCRB) Downgraded by Zacks Investment Research to Hold

Zacks Investment Research cut shares of Seres Therapeutics (NASDAQ:MCRB) from a buy rating to a hold rating in a report released on Thursday, Zacks.com reports.

According to Zacks, “Seres Therapeutics, Inc. offers microbiome therapeutics platform. It is focused on developing Ecobiotic microbiome therapeutics that treats dysbiosis in the colonic microbiome. Seres Therapeutics, Inc. is headquartered in Cambridge, Massachusetts. “

A number of other equities analysts also recently commented on the company. Canaccord Genuity restated a buy rating and issued a $11.00 target price on shares of Seres Therapeutics in a research note on Friday, May 8th. Oppenheimer decreased their target price on Seres Therapeutics from $8.00 to $7.00 and set an outperform rating for the company in a research note on Tuesday, March 31st. HC Wainwright restated a buy rating and issued a $8.00 target price on shares of Seres Therapeutics in a research note on Monday, March 23rd. ValuEngine upgraded Seres Therapeutics from a hold rating to a buy rating in a research note on Thursday, April 2nd. Finally, BidaskClub downgraded Seres Therapeutics from a buy rating to a hold rating in a research report on Friday, May 15th. One analyst has rated the stock with a hold rating and eight have issued a buy rating to the company. The stock currently has a consensus rating of Buy and an average target price of $7.20.

Seres Therapeutics stock traded down $0.14 during midday trading on Thursday, hitting $5.29. The stock had a trading volume of 441,800 shares, compared to its average volume of 306,674. The business has a fifty day moving average price of $3.89 and a 200 day moving average price of $3.65. Seres Therapeutics has a 12 month low of $2.02 and a 12 month high of $5.59. The stock has a market cap of $377.52 million, a P/E ratio of -5.54 and a beta of 0.98.

Seres Therapeutics (NASDAQ:MCRB) last issued its earnings results on Thursday, May 7th. The biotechnology company reported ($0.28) EPS for the quarter, meeting the Zacks’ consensus estimate of ($0.28). The company had revenue of $8.19 million during the quarter, compared to analyst estimates of $8.01 million. As a group, equities research analysts forecast that Seres Therapeutics will post -1.01 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the company. Windsor Creek Advisors LLC acquired a new position in shares of Seres Therapeutics during the fourth quarter worth approximately $35,000. KBC Group NV lifted its position in Seres Therapeutics by 7,603.7% in the fourth quarter. KBC Group NV now owns 10,400 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 10,265 shares during the period. PagnatoKarp Partners LLC acquired a new stake in Seres Therapeutics in the first quarter worth approximately $36,000. Advisor Group Holdings Inc. acquired a new stake in Seres Therapeutics in the first quarter worth approximately $38,000. Finally, Virtu Financial LLC acquired a new stake in Seres Therapeutics in the fourth quarter worth approximately $39,000. Institutional investors and hedge funds own 91.79% of the company’s stock.

Seres Therapeutics Company Profile

Seres Therapeutics, Inc, a microbiome therapeutics platform company, engages in developing biological drugs that are designed to treat disease by restoring the function of a dysbiotic microbiome. The company's advanced program is the SER-109, which is in Phase III clinical development for reducing recurrent clostridium difficile infection (CDI).

Recommended Story: How prevalent are 12b-1 fees?

Get a free copy of the Zacks research report on Seres Therapeutics (MCRB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Seres Therapeutics (NASDAQ:MCRB)

Receive News & Ratings for Seres Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Seres Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.